Opinion

Allergy Therapeutics is a pioneering immunology company, specialised in the research and development of allergy and immune disorder treatments that target the cause, rather than just manage the symptoms. Alan Bullimore, Head of Business Innovation spoke to Lu Rahman about the company’s work and the challenges and opportunities of this market. LR: Describe Allergy Therapeutics […]

Valence’s co-founder and CEO, Daniel Cohen, spoke to Lu Rahman about the company’s plan to empower drug discovery scientists with AI-enabled drug design LR:  Outline of the company and its main initiatives DC: Valence is an interdisciplinary team of scientists and engineers out of Mila, the world’s largest deep learning research institute. At Valence, we […]

Viswa Colluru, PhD, founder and CEO of Enveda Biosciences talks to Lu Rahman about the company’s chemical search engine and its work harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges.  LR: Describe what Enveda does and some of its current work / initiatives. VC: Enveda is building the first high-resolution […]

Drug discovery is complex and the expertise it requires is vast. Matthew A. Clark, Chief Executive Officer, X-Chem, talks to Lu Rahman about the company’s experience of collaboration and how it enables innovation, flexibility and problem-solving. Drug discovery is the most interdisciplinary of all scientific endeavours, says Clark. “To successfully discover and develop life-improving medicines, […]

Claire Hill, Head of Strategic Marketing at IDBS, explores ways in which the pharmaceutical sector can reap the benefits of an increasingly digital world. The Covid-19 pandemic pushed the process of drug development into the spotlight in a new way. The challenge for biopharmaceutical companies—to create, test, and manufacture a vaccine in months rather than […]

RSV is a complicated virus, and traditional vaccine methods have not worked. But UW’s Institute for Protein Design may have solved the problem using computational design. With the help of an innovative computer program, Icosavax has constructed virus-like particles (VLPs) using a two-part assembly (like a soccer ball). Adam Simpson, CEO of Icosavax, talks to […]

bit.bio is a synthetic biology company working on producing every human cell type at scale, with the aim of transforming the research and medicine landscape. Farah Patell-Socha, PhD, VP Research Products tells Lu Rahman about some of the company’s groundbreaking work in this field and the benefits it is creating for disease modelling and drug […]

Lu Rahman talks to John Fuller, Product Manager–Drug Discovery, Beckman Coulter Life Sciences about the pandemic’s impact on this global organisation and its customers — and what to expect in 2021 and beyond. Not surprisingly, the emergence of the Covid-19 pandemic in 2020 caused hundreds, if not thousands of drug discovery research labs worldwide to […]

Andrew Aldridge, Partner at  Deepbridge Capital explains why life science sector has shot up the UK investment agenda as vaccinations are rolled out. The past twelve months have showcased the importance of medical developments like never before. Innovation in the life sciences sector has been headline news around the globe and all aspects of the healthcare system have been under the […]